Similarly, the ongoing SYNBIoSe trial (ClinicalTrials.gov Identifier: NCT02284984) is investigating the effects of combined therapy with anti-CD20 and anti-BLyS on SLE pathogenic autoantibodies. Here, TNFSF13B is linked to systemic lupus erythematosus.